Canaccord analyst Austin Moeller lowered the firm’s price target on Bioceres (BIOX) to $6.50 from $7 and keeps a Buy rating on the shares. The firm noted management announced its intent to pivot away from Bioceres’ seed business to focus on trait development and leverage key partnerships to expand its footprint internationally.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOX: